Exicure received a Nasdaq extension through December 2, 2026, to regain compliance with the minimum $2.5 million stockholders' equity requirement after failing initial listing standards in June 2026. The company must demonstrate compliance by this deadline or face potential delisting proceedings. Exicure is a biotechnology company.
